Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Tuesday, November 7th.
Several other research firms have also commented on CLDX. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a report on Tuesday, September 26th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research lowered Celldex Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, July 17th. Finally, BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.31.
Shares of Celldex Therapeutics (NASDAQ CLDX) opened at $2.90 on Tuesday. Celldex Therapeutics has a one year low of $2.20 and a one year high of $4.48.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 77.3% compared to the same quarter last year. equities analysts expect that Celldex Therapeutics will post -0.93 EPS for the current year.
Hedge funds have recently modified their holdings of the stock. TSP Capital Management Group LLC grew its holdings in Celldex Therapeutics by 6.8% in the 2nd quarter. TSP Capital Management Group LLC now owns 1,135,748 shares of the biopharmaceutical company’s stock worth $2,805,000 after buying an additional 72,500 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Celldex Therapeutics by 42.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares in the last quarter. Meditor Group Ltd grew its holdings in Celldex Therapeutics by 39.9% in the 2nd quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock worth $14,326,000 after buying an additional 1,654,100 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Celldex Therapeutics by 426.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock valued at $1,778,000 after purchasing an additional 398,978 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Celldex Therapeutics by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock valued at $1,943,000 after purchasing an additional 5,616 shares in the last quarter. 51.37% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Celldex Therapeutics, Inc. (CLDX) Rating Reiterated by HC Wainwright” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/25/celldex-therapeutics-inc-cldx-given-buy-rating-at-hc-wainwright.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.